| Project/Area Number |
04670795
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine, Faculty of Medicine |
|---|
Principal Investigator |
HAGIWARA Akeo Institution, Department, Title of Position Kyoto Prefectural University of Medicine, Faculty of Medicine, Assistant, 医学部, 助手 (90198648)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHASHI Toshio Institution, Department, Title of Position Kyoto Prefectural University of Medic, 医学部, 教授 (50079828)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1993: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1992: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | Microspheres / Peritoneal Carcinomatosis / Anti-Cancer Drugs / Drug-Delivery-System |
|---|
| Research Abstract |
A new drug-delivery formulation of cisplatin, whereby cisplatin was incorporated in lactic acid oligomer microspheres (CDDP-MS), was developed in a dosage form for peritoneal carcinomatosis. In vitor study showed that CDDP-MS released 70% of the incorporated cisplatin slowly during a period of 3 weeks.
CDDP-MS resulted in a higher cisplatin concentration in tissue adjacent to the peritoneum for a longerperiod of time, and the concentration of cisplatin in the rest of the body was lower than that delivered by the cisplatin solution.
The 50% lethal dose value, determined by the Litchfield-Wilcoxon method in mice was 23.8 mg/kg in CDDP-MS in terms of cisplatin, whereas in the cisplatin solution it was 13.5 mg/kg body weight.
CDDP-MS, tested in experimental peritoneal carcinomatosis induced by transplantable M 5076 tumor in mice, enhanced therapeutic effects when compared with the same toxicity dosage of cisplatin solution.
CDDP-MS, at cisplatin 100 mg/person, was given intraperitoneally to 14 patients and 200 mg/person to one patient for the treatment of malignant ascites. The ascites disappeared completely in 8 of the 15 patients, and partially in 5 patients, for an over-all response rate of 87%. The side effects were mild, and tolerable for patients.
Microspheres incorporating methotrexate or 5-FU were developed to release the incororating anti-cancer drugs slowly for a long period of time in vitro.
|
